SCHEMBL23218491

SCHEMBL23218491

CCOC(=O)c1coc2c(OCc3nccs3)cc(Br)cc12

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP9 P14780 1/20 0.37
MMP13 P45452 1/20 0.37
ADAM17 P78536 1/20 0.37
ALDH1A1 P00352 5/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
PIM1 P11309 1/20 0.35
PIM2 Q9P1W9 1/20 0.35
MAPK1 P28482 1/20 0.35
MAOB P27338 1/20 0.34
GABRA1 P14867 1/20 0.34
GABRB1 P18505 1/20 0.34
GABRA3 P34903 1/20 0.34
GABRB2 P47870 1/20 0.34
MAPT P10636 2/20 0.34
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
PKM P14618 1/20 0.34
TBK1 Q9UHD2 1/20 0.34
GAA P10253 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29852830 1.00 MMP9 (0.37) MMP9MMP13ADAM17ALDH1A1SMN1; SMN2
SCHEMBL29340691 0.88 PIM1 (0.41) MMP9MMP13ADAM17PIM1PIM2
SCHEMBL29852957 0.82 PIM1 (0.52) ALDH1A1SMN1; SMN2PIM1PIM2MAPK1
SCHEMBL23218355 0.82 PIM1 (0.52) ALDH1A1SMN1; SMN2PIM1PIM2MAPK1
SCHEMBL29852863 0.80 MAOB (0.41) ALDH1A1SMN1; SMN2MAPK1MAOBMAPT
SCHEMBL23218392 0.80 MAOB (0.41) ALDH1A1SMN1; SMN2MAPK1MAOBMAPT
SCHEMBL29591301 0.80 MAOB (0.41) ALDH1A1SMN1; SMN2MAPK1MAOBMAPT
SCHEMBL23218148 0.79 MEN1 (0.33) MMP9MMP13ADAM17PIM1PIM2
SCHEMBL23218101 0.79 TBXAS1 (0.39) MMP9MMP13ADAM17ALDH1A1PIM1
SCHEMBL29852692 0.79 TBXAS1 (0.39) MMP9MMP13ADAM17ALDH1A1PIM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 US disclosed
US-20240239752-A1 BICYCLIC HETEROAROMATIC INHIBITORS OF KLK5 WILMINGTON TRUST, NATIONAL ASSOCIATION 2024-07-18 US disclosed
US-20240239752-A1 BICYCLIC HETEROAROMATIC INHIBITORS OF KLK5 WILMINGTON TRUST, NATIONAL ASSOCIATION 2024-07-18 US disclosed
US-20240239752-A1 BICYCLIC HETEROAROMATIC INHIBITORS OF KLK5 WILMINGTON TRUST, NATIONAL ASSOCIATION 2024-07-18 US disclosed
CN-117120419-A KLK5 bicyclic heteroaromatic inhibitors 拜奥克里斯特制药公司 2023-11-24 CN disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240239752-A1 BICYCLIC HETEROAROMATIC INHIBITORS OF KLK5 KLK5, KLK1, KLKB1 MMP9 779/4885MMP13 239/4885ADAM17 452/4885
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB MMP9 538/4885MMP13 438/4885ADAM17 542/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB MMP9 640/4885MMP13 913/4885ADAM17 126/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.